NYSE: PFEPfizer Inc Stock Forecast, Predictions & Price Target
Analyst price target for PFE
Based on 11 analysts offering 12 month price targets for Pfizer Inc.
Min Forecast
$36.00-4.76%
Avg Forecast
$41.55+9.91%
Max Forecast
$53.00+40.21%
Should I buy or sell PFE stock?
Buy
Strong Buy
4 analysts 30.77%
Buy
1 analysts 7.69%
Hold
8 analysts 61.54%
Sell
0 analysts 0.00%
Strong Sell
0 analysts 0.00%
Forecast return on equity
Is PFE forecast to generate an efficient return?
Company
28.49%
Industry
55.93%
Market
-1.26%
PFE's Return on Equity is forecast to be high in 4 years (28.49%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast
Forecast return on assets
Is PFE forecast to generate an efficient return on assets?
Company
10.30%
Industry
15.10%
Market
11.45%
PFE is forecast to generate lower Return on Assets (10.30%) than the US Drug Manufacturers - General industry average (15.10%)
Forecast
PFE earnings per share forecast
What is PFE's earnings per share in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$2.84+11.50%
Avg 2 year Forecast
$2.84+11.18%
Avg 3 year Forecast
$3.08+20.78%
PFE's earnings are forecast to grow at a rate of 5.69% per year, which is not exceptional
Forecast
PFE revenue forecast
What is PFE's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$48.2B-1.99%
Avg 2 year Forecast
$47.5B-3.53%
Avg 3 year Forecast
$49.3B+0.21%
PFE's revenue is forecast to grow at a rate of 0.07% per year, which is not exceptional
Forecast
PFE earnings growth forecast
How is PFE forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
5.69%
Industry
20.04%
Market
14.77%
PFE's earnings are forecast to grow slower (5.69% per year) than the US Drug Manufacturers - General industry average (20.04%)
Forecast
PFE's earnings are forecast to grow slower (5.69% per year) than the US market average (14.77%)
Forecast
PFE revenue growth forecast
How is PFE forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
0.07%
Industry
6.42%
Market
5.69%
PFE's revenues are forecast to grow slower (0.07% per year) than the US Drug Manufacturers - General industry average (6.42%)
Forecast
PFE's revenues are forecast to grow slower (0.07% per year) than the US market average (5.69%)
Forecast
Pfizer Stock Forecast FAQ
Is Pfizer Stock a good buy in 2020, according to Wall Street analysts?
The consensus among 13 Wall Street analysts covering (NYSE: PFE) stock is to Buy PFE stock.
Out of 13 analysts, 4 (30.77%) are recommending PFE as a Strong Buy, 1 (7.69%) are recommending PFE as a Buy, 8 (61.54%) are recommending PFE as a Hold, 0 (0.00%) are recommending PFE as a Sell, and 0 (0.00%) are recommending PFE as a Strong Sell.
What is PFE's Price Target?
According to 11 Wall Street analysts that have issued a 1 year PFE price target, the average PFE price target is $41.55, with the highest PFE stock price forecast at $53.00 and the lowest PFE stock price forecast at $36.00.
On average, Wall Street analysts predict that Pfizer's share price could reach $41.55 by Oct 15, 2021. The average Pfizer stock price prediction forecasts a potential upside of 9.91% from the current PFE share price of $37.80.
What is PFE's earnings growth forecast for 2020-2022?
(NYSE: PFE) Pfizer's forecast annual earnings growth rate of 5.69% is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 20.04%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.77%.
Pfizer's earnings in 2020 is $14,171,000,000.On average, 6 Wall Street analysts forecast PFE's earnings for 2020 to be $15,794,058,813, with the lowest PFE earnings forecast at $15,109,147,811, and the highest PFE earnings forecast at $16,386,759,574. On average, 8 Wall Street analysts forecast PFE's earnings for 2021 to be $15,747,953,693, with the lowest PFE earnings forecast at $14,442,567,760, and the highest PFE earnings forecast at $19,386,369,801.
In 2022, PFE is forecast to generate $17,108,887,962 in earnings, with the lowest earnings forecast at $15,442,437,836 and the highest earnings forecast at $19,330,821,464.
What is PFE's revenue growth forecast for 2020-2022?
(NYSE: PFE) Pfizer's forecast annual revenue growth rate of 0.07% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 5.69%.
Pfizer's revenue in 2020 is $49,197,000,000.On average, 3 Wall Street analysts forecast PFE's revenue for 2020 to be $267,840,918,661,883, with the lowest PFE revenue forecast at $259,065,670,039,002, and the highest PFE revenue forecast at $277,369,569,386,820. On average, 4 Wall Street analysts forecast PFE's revenue for 2021 to be $263,642,408,665,597, with the lowest PFE revenue forecast at $242,904,714,456,802, and the highest PFE revenue forecast at $304,920,045,001,546.
In 2022, PFE is forecast to generate $273,850,482,216,653 in revenue, with the lowest revenue forecast at $253,083,780,665,994 and the highest revenue forecast at $305,939,245,898,730.
What is PFE's Earnings Per Share (EPS) forecast for 2020-2022?
(NYSE: PFE) Pfizer's current Earnings Per Share (EPS) is $2.55. On average, analysts forecast that PFE's EPS will be $2.84 for 2020, with the lowest EPS forecast at $2.72, and the highest EPS forecast at $2.95. On average, analysts forecast that PFE's EPS will be $2.84 for 2021, with the lowest EPS forecast at $2.60, and the highest EPS forecast at $3.49. In 2022, PFE's EPS is forecast to hit $3.08 (min: $2.78, max: $3.48).
What is PFE's forecast return on equity (ROE) for 2020-2023?
(NYSE: PFE) forecast ROE is 28.49%, which is considered strong.
What is PFE's forecast return on assets (ROA) for 2020-2023?
(NYSE: PFE) forecast ROA is 10.30%, which is lower than the forecast US Drug Manufacturers - General industry average of 15.10%.
©2020 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
